Currently, categorization based on cluster analysis by objectively grasping the diversity of pathology is being conducted and the diversity of asthma is being categorized as phenotypes. Clinically, there is categorization based on aging and on allergic diathesis which is clinically useful; however, it has not, up to now, come to the point of selection based on phenotype. Subsequently, what is desired is the establishment of phenotype categorization for the purpose of materialization of treatment strategy which corresponds to individual cases. This study elaborates on order-made medicine while considering phenotype.
| INTRODUCTION
Regarding asthma, the reactivity for progress and treatment differs for each patient and it has been advocated that it is not a single disease, but is a syndrome whereby the main complaint is asthma and dyspnea. It is thought that various genetic and environmental factors are involved and the clinical image is diverse, hence phenotype categorization based on index such as symptoms, inducement, progress, outbreak period, bronchitis, respiratory functions. However, whether these categorizations have a clinical advantage is still unclear. Recently, many etiologic genes have been reported and pharmacogenetics study has been conducted. However, at this stage, it has not come yet to the point where it can be introduced into actual medical practice, the current state is that there are still few reports on an improvement of treatment achievement through genetic analysis.
There is expectation to apply the purpose of phenotype categorization to things such as prevention of disease, control, and treatment selection.
| ASTHMA PHENOTYPE
Before now, phenotype categorization based on index such as outbreak age, course, severity, inducement (atopic type and nonatopic type, virus infection, etc.), reactivity to treatment (such as steroid reactivity), bronchitis, induced sputum,and FeNO (fractional exhaled nitric oxide) has been conducted. Moreover, a more objective categorization using statistical method such as cluster analysis has been applied and this study introduces representative categorization.
| Cluster analysis by Haldar et al.
Haldar et al. has categorized asthma into five phenotypes through cluster analysis by targeting a secondary care asthma group of 187 cases inclusive of heavy asthma.
1 ( Figure 1 ).
Group 1: Early-onset atopic asthma (early age onset, atopic type): respiratory tract reversibility was both strong and especially eosinophilic inflammation was strong. Deterioration repeatedly occurs. 
| Cluster analysis of SARP registration examples
Moore et al. Lung and Blood Institute (NHLB1) (over 12 years old 726 cases) and conducted cluster analysis using respiratory functionality (before infusion of bronchodilating preparations and FEV after infusion) and onset age and categorized 5 categories 2 ( Figure 2 ). Table 2 .
| ASTHMA TREATMENT OF PHENOTYPE CATEGORIZATION
As there exist diverse phenotypes for asthma, treatment selection should be made which is in line with clinical characteristics and individual patients' background. Order-made medicine which provided 
| Eosinophil type asthma, noneosinophil asthma comparison:
From the standpoint of phenotype categorization or cluster analysis, the existence of onset age, natural progress, the existence of causative factor of atopy is an important factor and specifically from the standpoint of treatment selection, as a phenotype for reference, attention is focused on eosinophil asthma and noneosinophil 3 shows that the number of eosinophil through induced sputum examination is useful in the selection of asthma treatment.
| Asthma with allergic rhinitis
Allergic rhinitis is frequently associated with adult-onset asthma.
Tanimoto et al. 4 compared the time of onset between the two conditions and reported that the onset of allergic rhinitis was 9.7 years earlier on average than that of asthma in adult patients with asthma with age 30 years or older. In 2009, a nationwide study in Japan (SACRA survey) reported that 67.3% of adult patients with asthma had allergic rhinitis. 5 As allergic rhinitis is frequently associated with asthma and may affect the control of asthma, we consider that LTRA and Th2 cytokine inhibitor are useful to improve the symptoms of asthma and rhinitis.
| About refractory asthma
As for refractory asthma based on asthma prevention・management guideline 2012, even when treatment step 4 treatment is conducted, it is positioned that it is asthma which belongs to the most serious continuous type whereby symptoms occur every day. Refractory asthma continues for a long time and occurs in nonatopic type for adult occurrence type and risk factors include female gender, obesity, smoking, and aspirin sensitivity, and it assumes 10-15% of adult asthma patients and treatment is extremely difficult. As for refractory asthma phenotype, the aggravation of frequency of occurrence, the irreversibility of airflow restriction, steroid dependency, and resistance is crucial. However, as for phenotype which is effective for reactivity against prognosis and treatment, there are only a few which are established, and through analyzing these phenotypes, attempt is made to categorize the disease types.
| Anti-IgE antibody treatment against atopic type refractory asthma
Among high-dose ICS and LABA, LTRA, theophylline sustained release tablet, even with the combined use of two types, when control was not good, an oral steroid drug was used. Currently, there is high recognition of the effect of the use of molecular target drug anti-IgE monoclonal antigen (omalizumab). As for omalizumab, it is positive for perennial inhalation antibody, and the serum total IgE value 30-700 IU/mL serious cases are applicable and it combines with isolated IgE antibody Cr3 and by controlling activation of IgE of inflammatory cell such as mast cells, it is used in the treatment of refractory asthma.
The effectiveness rate is 60%, and there is a need for more research on responder selection method for omalizumab to enhance the treatment effect.
| About LTRA-resistant asthma
In about 30% of asthma patients, there is genetic polymorphism of LTC4 synthesis enzyme, and there is difference in LTRA effect. 6 However, normally it is difficult to measure LTC4 synthetic enzyme gene. Even with a dosage of furuchikazone (FP200-4-μg/d) for those where control cannot be achieved for mid-range and heavy range continuation type LTRA resistance adult asthma patients, when giving medication of Th2 cytokine inhibitor drug, effect was achieved. From the perspective of personalized medicine, it can be thought that to
give cytokine inhibitor drug for LTRA resistance adult asthma, could be a choice.
| About aged asthma
It has been diagnosed that among those over 65 years of age, 4-13% have cancer; however, the diagnosis of asthma in the aged is not yet sufficient. Moreover, it seems that the mortality rate among aged asthma patients is due to insufficient treatment, aggravation of adherence, and many other causes such as complications. However, the possibility of immunosenescence has been indicated. 7 When categorizing aged asthma based on onset period, it can be categorized into continuation of pediatric asthma, long-standing/childhood-onset asthma which reoccurs after remission, and late onset asthma. 8 Busses has, regardless of onset period, indicated that immune aging is in the background of aged asthma. Moreover, there are three risk factors of respiratory function deterioration, for both men and women, which are aging, smoking, and asthma. Comparing asthma which occurs in those aged over 65 and in nonaged asthma, in aged asthma, the decline with age the flow of volume in one-second is large and although respiratory tract reversibility was seen, in nonaged onset, there was a remarkable deterioration of respiratory function. Respiratory tract indicated reversible response and remodeling impact was implied.
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Moreover in aged onset, night symptoms were small and seasonality was seen mostly during the winter, and the most common feature was COPD (chronic obstructive pulmonary disease). On the other hand, in nonaged onset, there were high incidence of night symptoms and seasonality occurred mostly during spring. Also atopic causative factors were involved and daily fluctuation was seen as being large.
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For further clarification, the authors showed the pathology of aged asthma; among asthma patients more than 65 years old and above for which the onset age is clear, cases without smoking history were separated into nonaged onset group (15 cases) and those aged onset group over 65 years old (15 cases). As a result of comparative discussion about IOS (impulse oscillation system), level of severity, atopy causative factor, inflammation of respiratory tract and spirometry, the level of severity was, compared to the nonaged onset type, aged onset group the number of light cases was of an increasing tendency.
In aged onset asthma as well, the involvement of atopy causative factor existed and in respiratory tract inflammatory marker, there was no significant difference based on onset age. As for level of urgency, compared with nonaged onset group, with aged onset group, there was higher tendency of light cases. Among aged onset asthma as well, there existed involvement of atopic causative types and with respiratory tract inflammation marker, there was no significant difference in onset age. As for respiratory refractability, regarding respiratory tract sensitivity, there was no significant difference in onset age. Moreover, from the standpoint of spirometry IOS results, regarding aged onset asthma over 65 years of age, it was indicted that there is possibility for respiratory functionality and decline with age of peripheral respiratory impediment to progress in a comparatively short period. The symptoms of aged asthma are slight, and there is need to be sufficiently careful of diagnosis. To prevent asthma death in the future, it is thought that ICS early introduction is required. However, for aged asthma, in addition to respiratory function and deterioration in physiological function, treatment has become difficult due to deterioration in adherence due to a decline in the level of understanding and memory, and as for midaged onset type patients, compared with young onset type patients, there is less experience in terms of treatment, and in the handling inhalation devices. As progress in the selection of treatment drugs is expanding and inhalation devices are diversifying, it can be seen to complicate the acquiring of inhalation method. With the aged, there is high involvement of peripheral respiratory tract issues and there is the possibility that inhalation drugs will not reach the peripheral respiratory tract. Therefore, it is thought that inhalation should be conducted regularly.
The author presented a proposal for tailor-made treatment for asthma phenotypes described in a) to f) in Table 3 .
| CONCLUSION
The phenomenon of asthma is very heterogeneous and is recognized as not a single disease but is a syndrome with asthma and respiratory difficulty as a main complaint. It can be thought that with each phenotype, there is a need for an order-made medicine in accordance with each patient. When a sufficient treatment result cannot be attained although appropriate treatment is conducted, before serious asthma is assumed, it is important to think of the causes based on each phenotype such as environmental factors, complications, drug resistivity, confirmation of treatment adherence, mistakes in inhalation method. In this regard, there is a great need to consider phenotype elements for order-made medicine.
In conclusion, phenotype is based on clinical symptoms such as respiratory function, onset age, blood biochemical examination values; the end type is categorization based on genes and molecular biological mechanism, and although it has been clarified that for asthma there are diversified phenotypes, however, in the background, it is thought that there exist diversified end types. It is expected that end type and phenotype related should be elucidated and order-made treatment appropriate for each individual patient be made possible. Currently, we are groping for a way toward treatment selection based on phenotype; however, we have not yet come to the point of selecting the appropriate treatment for all. Specifically, there are serious, difficultto-cure cases for aged asthma. There are also issues of asthma death which might be prevented based on finding the best ways possible for device selection and in the improvement of adherence.
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